Tamar Thompson Biography and Net Worth

Director of Avidity Biosciences

Tamar Thompson is a distinguished health policy strategist, government affairs leader and market access executive with a diverse background across multiple healthcare sectors and therapeutic categories including rare disease, immunology, oncology and cardiovascular disease. She has more than twenty years of leadership experience in health care, including a focus on developing strategic and tactical recommendations to ensure optimal reimbursement and market access for rare disease products. Ms. Thompson currently serves as the Vice President, US Government Affairs and Policy for Alexion Pharmaceuticals, Inc. and as the Chair of the Board of Alexion’s Charitable Foundation. Prior to joining Alexion, Ms. Thompson served as head, federal executive branch strategy and state government affairs for Bristol-Myers Squibb Company. She also served as a strategic policy advisor and consultant for premiere Washington, DC based firms, including ADVI, Kimbell and Associates and Avalere Health. Ms. Thompson holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress California.

How do I contact Tamar Thompson?: The corporate mailing address for Ms. Thompson and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at amy@juniper-point.com. Learn More on Tamar Thompson's contact information.
Has Tamar Thompson been buying or selling shares of Avidity Biosciences?: Tamar Thompson has not been actively trading shares of Avidity Biosciences during the past quarter. Most recently, Tamar Thompson sold 30,000 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $44.98, for a transaction totalling $1,349,400.00. Learn More on Tamar Thompson's trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Kathleen Gallagher (Insider), Steven Hughes (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 855,410 shares worth more than $31,187,816.48. The most recent insider tranaction occured on April, 1st when insider Kathleen P Gallagher sold 5,875 shares worth more than $163,501.25. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 4/1/2025.

Tamar Thompson Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/7/2024	Sell	30,000	$44.98	$1,349,400.00

Tamar Thompson Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $26.60

$25.66

$27.02

50 Day Range

MA: $29.80

$24.08

$34.31

2 Week Range

Now: $26.60

$21.51

$56.00

Volume

1,005,713 shs

Average Volume

1,397,786 shs

Market Capitalization

$3.20 billion

P/E Ratio

N/A

Dividend Yield